Enterprise Value
-46.41M
Cash
86.61M
Avg Qtr Burn
-7.096M
Short % of Float
1.32%
Insider Ownership
16.67%
Institutional Own.
51.53%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IV Choline chloride Details Liver disease, Intestinal failure associated liver disease | Phase 3 Update | |
TARA-002 Details Lymphatic malformations, Bladder cancer, Non-muscle invasive bladder cancer, Cancer, Solid tumor/s | Phase 2 Initiation | |
TARA-002 Details Bladder cancer, Non-muscle invasive bladder cancer | Phase 1a Data readout |